Drug Discovery & Pharmaceuticals

RSS

AI-based strategy helps discover high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

31 Jan 2023

A high-throughput drug discovery assay for the endoplasmic reticulum aminopeptidase 1

The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.

31 Jan 2023

Massive clinical study on type 1 diabetes patients

A massive clinical study on an approved psoriasis drug is now underway. The drug will be tested on people who have just been diagnosed with type 1 diabetes. The drug, according to the theory, could preserve the patient’s remaining insulin production.

30 Jan 2023

Newly discovered enzyme tells specific molecules precisely how to arrange themselves

Just as a choreographer's notation tells a dancer to strike a particular pose, an enzyme newly discovered by Rice University scientists is able to tell specific molecules precisely how to arrange themselves, down to the angle of single hydrogen bonds.

30 Jan 2023

Scientists receive $10 million from HHMI for research on using viruses as therapeutic agents

Taking a bold step into a new era of biology, a team of scientists from the University of California San Diego, the J. Craig Venter Institute and Yale University has been awarded $10 million by the Howard Hughes Medical Institute to support research on using viruses as new therapeutic agents.

27 Jan 2023

Spikes protruding from red algae-derived metal-polysaccharide responsible for antimicrobial activities

Antibiotic resistant bacteria are becoming more and more of a concern as traditional sources of anti-microbial treatments become less effective.

27 Jan 2023

New spray can prevent infections and kill antibiotic-resistant bacteria

The World Health Organization ranks antibiotic resistance as one of the top ten threats to global health. There is therefore a great need for new solutions to tackle resistant bacteria and reduce the use of antibiotics.

27 Jan 2023

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

From Ubiquigent Limited 23 Jan 2023

New method to treat MRSA infections with penicillin-type drugs

Researchers from the University of Galway have reported a new discovery that could enhance treatment options for superbug MRSA infections using penicillin-type antibiotics that have proven ineffective on their own.

18 Jan 2023

Using fungi to transform ocean plastic waste into key pharmaceutical components

Research on fungi underway at the University of Kansas has helped transform tough-to-recycle plastic waste from the Pacific Ocean into key components for making pharmaceuticals.

18 Jan 2023

Intracellular drug delivery using a novel nano transporter

The effectiveness of a novel nano molecule as a drug delivery system has been examined in a recent study by the University of Barcelona.

From University of Barcelona 13 Jan 2023

New solution to treat diseases caused by exaggerated inflammation

A recent study guided by the Instituto Gulbenkian de Ciência (IGC) shows how anticancer drugs reduce inflammation, establishing them as prospective sepsis treatments.

11 Jan 2023

Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents

Gyros Protein Technologies AB today introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits.

From Gyros Protein Technologies AB 30 Nov 2022

Chemical-biological method to upcycle plastic waste into pharmacologically useful products

Plastic waste is one of the most significant ecological and economic problems of our time. In the journal Angewandte Chemie, a research team has now introduced a chemical–biological method for upcycling polyethylene waste: catalytic cleavage is used to make carboxylic diacids that are subsequently converted into pharmacologically useful natural products by genetically engineered fungi.

29 Nov 2022

Tackling epilepsy with a potential new drug

One of the epilepsy types that are most prevalent worldwide is temporal lobe epilepsy (TLE). Although there are symptomatic medications available, one-third of TLE patients are still not responding to the current course of treatment, necessitating the urgent need for new drug targets.

25 Nov 2022

AI creates artificial DNA to control cell protein production

Researchers at Chalmers University of Technology in Sweden have developed synthetic DNA that uses artificial intelligence to control the production of proteins in cells.

25 Nov 2022

Novel approach increases the protein production efficiency of synthetic mRNAs

A group of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) recently figured out a way to improve the efficiency of synthetic mRNA protein production by up to tenfold.

24 Nov 2022

Molecular motion of “undruggable” proteins reveals drug-binding sites

“Undruggable” proteins, whose structures and roles in disease are known but who appear unable to be targeted by drugs that will bind to them, present some of the hardest problems in disease treatment.

23 Nov 2022

Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company.

From Optibrium Ltd. 23 Nov 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

Drug Discovery & Pharmaceuticals

AI-based strategy helps discover high-affinity antibody drugs

A high-throughput drug discovery assay for the endoplasmic reticulum aminopeptidase 1

Massive clinical study on type 1 diabetes patients

Newly discovered enzyme tells specific molecules precisely how to arrange themselves

Scientists receive $10 million from HHMI for research on using viruses as therapeutic agents

Spikes protruding from red algae-derived metal-polysaccharide responsible for antimicrobial activities

New spray can prevent infections and kill antibiotic-resistant bacteria

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

New method to treat MRSA infections with penicillin-type drugs

Using fungi to transform ocean plastic waste into key pharmaceutical components

Intracellular drug delivery using a novel nano transporter

New solution to treat diseases caused by exaggerated inflammation

Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents

Chemical-biological method to upcycle plastic waste into pharmacologically useful products

Tackling epilepsy with a potential new drug

AI creates artificial DNA to control cell protein production

Novel approach increases the protein production efficiency of synthetic mRNAs

Molecular motion of “undruggable” proteins reveals drug-binding sites

Optibrium appoints Ian Smith as Chief Technology Officer

Atypical antibody shows extremely potent zika-resistant activity

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics